<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03730961</url>
  </required_header>
  <id_info>
    <org_study_id>CV013-034</org_study_id>
    <secondary_id>2018-000970-31</secondary_id>
    <nct_id>NCT03730961</nct_id>
  </id_info>
  <brief_title>An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Cross-over Phase 2 Study of Continuous 8-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function Given a Standard Dose of Loop Diuretic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate continuous 8-hour introductions of BMS-986231 in
      participants with heart failure and weakened heart function given a standard dose of
      diuretic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Actual">January 9, 2020</completion_date>
  <primary_completion_date type="Actual">January 9, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>4-hour urinary output following furosemide administration</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fractional excretion of sodium</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional excretion of potassium</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Furosemide urinary concentration</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Furosemide plasma concentration</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of urinary sodium to urinary furosemide after BMS-986231 compared to placebo</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically relevant hypotension during infusion</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values, vital signs, ECGs, telemetry, and physical examinations</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Cardiac Failure</condition>
  <condition>Myocardial Failure</condition>
  <condition>Congestive Heart Failure</condition>
  <condition>Heart Decompensation</condition>
  <arm_group>
    <arm_group_label>Placebo+Diuretic to BMS-986231+Diuretic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986231+Diuretic to Placebo+Diuretic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986231</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>BMS-986231+Diuretic to Placebo+Diuretic</arm_group_label>
    <arm_group_label>Placebo+Diuretic to BMS-986231+Diuretic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>BMS-986231+Diuretic to Placebo+Diuretic</arm_group_label>
    <arm_group_label>Placebo+Diuretic to BMS-986231+Diuretic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>BMS-986231+Diuretic to Placebo+Diuretic</arm_group_label>
    <arm_group_label>Placebo+Diuretic to BMS-986231+Diuretic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Left ventricular ejection fraction &lt;45%, as assessed by echocardiography, a multigated
             acquisition (MUGA) scan or magnetic resonance imaging (MRI) scan within 18 months

          -  On stable chronic guideline-directed therapy for HF including chronic loop diuretics,
             ACEi, ARBs, MRAs, ARNI or / and Î²-blockers as tolerated, with no changes of these
             medications in the past 2 weeks

          -  At least an oral dose of 40 mg of furosemide/day or equivalent (20 mg torsemide, 1 mg
             bumetamide)

        Exclusion Criteria:

          -  SBP &lt; 115 mm Hg or &gt; 180 mm Hg at screening or pre-randomization

          -  Heart rate &lt; 50 beats per minute (bpm) or &gt; 120 bpm at screening or pre-randomization

          -  Primary HF etiology attributable to either restrictive/obstructive cardiomyopathy,
             idiopathic hypertrophic or uncorrected severe valvular disease

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glasgow Clinical Research Facility</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Pharmacology</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

